Vernalis

Vernalis (R&D) is a Cambridge-based contract drug discovery organisation specialising in fragment-based and structure-based drug discovery.

The company integrates structural biology, biophysics, NMR spectroscopy, DNA-encoded library screening, medicinal chemistry, and computational approaches to identify and progress small molecule hits against challenging targets.

Vernalis collaborates with pharmaceutical and biotechnology partners on both short- and long-term programmes across oncology, neurodegeneration, and anti-infectives. It operates as a wholly owned subsidiary of HitGen Inc.